Moderna, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stéphane Bancel
- Full Time Employees
- 4,700
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Company News
Moderna, Google DeepMind, Biocon on AI in Science
Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
Here's Why Moderna (MRNA) Fell More Than Broader Market
The Big 3: PLTR, MRNA, DELL
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
Breakfast News: The Quarter in Charts
Why Moderna Stock Surged Today
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Moderna stock fires past 52-week high: what's behind Friday's rally?
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
3 Stocks That Have More Than Doubled the S&P 500’s Return This Year